Pilz et al. (Fluids Barriers CNS 17:7; 2020) investigated how CSF CXCL13 concentrations are influenced by CXCL13 serum concentrations and blood-CSF barrier (BCSFB) function, comparing the impact of serum CXCL13 levels and Qalbumin (CSF albumin/serum albumin) on CSF CXCL13 among patients with CNS inflammation categorized as CXCL13 negative, low, medium, or high. Among all CXCL13 groups, their results showed no correlation between CSF CXCL13 concentrations and serum CXCL13 or Qalbumin. The authors argue that, in contrast to other proteins, CXCL13 passage across the BCSFB does not occur, regardless of BCSFB function, and is instead solely influenced by intrathecal production. In contrast to the authors’ findings, in our studies including both non-inflammatory neurological disorders (NIND; n = 62) and multiple sclerosis (MS) patients we observed a significant correlation between serum CXCL13 concentrations and CSF CXCL13 concentrations. We review several observations which may underlie these contrasting results, including (1) the impact of serum CXCL13 concentrations on CSF CXCL13 in patients with lower intrathecal CXCL13 production and thus lower CXCL13 concentrations (i.e. NIND and MS), (2) the proposed diffusion dynamics of the small molecule CXCL13 across the BCSFB, and (3) differing definitions of negative versus elevated CSF CXCL13 concentrations determined by an assay’s relative sensitivity. In conclusion, we argue that for patients with moderately elevated CSF CXCL13 concentrations, serum CXCL13 concentrations influence CSF CXCL13 levels, and thus the appropriate corrections including incorporation of CSF/serum ratios and Qalbumin values should be utilized.

中文翻译：

---

CSF CXCL13 浓度是否仅取决于鞘内产生？“血清、脑脊液和血-脑脊液屏障功能中的趋化因子CXCL13”评述

皮尔兹等人。(Fluids Barriers CNS 17:7; 2020) 研究了 CSF CXCL13 浓度如何受 CXCL13 血清浓度和血脑脊液屏障 (BCSFB) 功能的影响，比较了血清 CXCL13 水平和 Qalbumin（CSF 白蛋白/血清白蛋白）对 CSF CXCL13 的影响在被归类为 CXCL13 阴性、低、中或高的 CNS 炎症患者中。在所有 CXCL13 组中，他们的结果显示 CSF CXCL13 浓度与血清 CXCL13 或 Qalbumin 之间没有相关性。作者认为，与其他蛋白质相比，无论 BCSFB 功能如何，CXCL13 都不会通过 BCSFB，而仅受鞘内产生的影响。与作者的发现相反，在我们的研究中，包括非炎症性神经系统疾病（NIND；n = 62) 和多发性硬化 (MS) 患者，我们观察到血清 CXCL13 浓度和脑脊液 CXCL13 浓度之间存在显着相关性。我们回顾了一些可能构成这些对比结果的基础的观察结果，包括 (1) 血清 CXCL13 浓度对鞘内 CXCL13 产生较低的患者的 CSF CXCL13 的影响，从而降低 CXCL13 浓度（即 NIND 和 MS），（2）建议的扩散动力学BCSFB 中小分子 CXCL13 的差异，以及 (3) 由测定的相对灵敏度确定的阴性与升高的 CSF CXCL13 浓度的不同定义。总之，我们认为对于 CSF CXCL13 浓度中度升高的患者，血清 CXCL13 浓度影响 CSF CXCL13 水平，